[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibiotic-resistant-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibiotic-resistant-infection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,71,108,136,163,190,215,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100452263","phase-2-antibiotic-impregnated-bone-graft-to-reduce-infection-in-hip-replacement-100452263",false,"NCT05169229","Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.","Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. The ABOGRAFT Trial","ABOGRAFT","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Hip arthroplasty requiring bone graft\n3. Willing to provide informed consent.\n4. For women of childbearing potential; a negative pregnancy test prior to reoperation.\n\nExclusion Criteria:\n\n1. Ongoing prosthetic joint infection\n2. Known allergies and contraindications for the use of vancomycin or tobramycin\n3. Mental inability, reluctance, or language difficulties that according to investigator judgement, result in difficulty understanding the meaning of study participation\n4. Expected difficulties to complete 2-year follow-up\n5. Females of child bearing potential not using contraception\n6. Pregnant females\n7. Nursing females","ALL","18 Years",{"count":20,"type":21},1100,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Total hip replacement is the most successful treatment modern healthcare can offer patients to regain quality of life. Periprosthetic joint infection (PJI) is the most common and devastating complication after total hip replacement (THR). Between 0.5 to 2% of primary THR (first time hip replacement), and 8-10% of revision THR (replacement of a hip prosthesis) will become infected.1 The introduction of local antibiotics blended into bone cement has led to a reduction in postoperative infection in primary THR by half.2 Unfortunately, cement can't always be used in relevant quantities.\n\nThe number of primary and revision surgeries of the hip is projected to increase dramatically. Therefore, the need for a feasible infection prophylaxis that is applicable for complex primary and revision THR in addition to antibiotics loaded cement is urgent.\n\nImpacted morselized bone allograft is often used in (revision) THR to fill bone defects. Morselized allograft has been used as a carrier for local antibiotic treatment in multiple pilot studies and appears to be an attractive and effective treatment option, both for already infected joints and as a prophylactic measure in high-risk patients (e.g. THR revision surgeries). Nonetheless, a pivotal trial to support its use in THR is lacking. The aim of this pragmatic randomized controlled double blinded drug trial is to investigate whether antibiotic impregnated bone graft (AIBG) decreases the risk of infection after hip arthroplasty compared to controls treated with placebo impregnated bone graft. Patients scheduled for elective THR will be randomized to receive AIBG or a placebo impregnated bone graft. The primary outcome variable will be the number of re-operations due to infections and PJI diagnoses 2 years postoperative.",[28,29,30,31],"Arthroplasty, Replacement, Hip","Osteoarthritis, Hip","Antibiotic Resistant Infection","Prosthetic Joint Infection","RECRUITING","2025-07-17",{"date":35,"type":36},"2025-07-22","ACTUAL",{"date":38,"type":36},"2022-04-01",{"date":40,"type":21},"2031-12",{"name":42,"class":43},"University Hospital, Linkoeping","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":4,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100506214","interventions-to-decrease-cre-colonization-and-transmission-between-hospitals-households-communities-and-domesticated-animals-100506214","NCT05871476","Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals","Interventions to Decrease Carbapenem Resistant Enterobacteriaceae Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals","I-CRECT","Inclusion Criteria:\n\n* All patients under 2 years old at the selected hospital are highly appreciated to join the study.\n\nExclusion Criteria:\n\n* Patients not from the selected hospital and individuals outside the selected province",true,"24 Months",{"count":56,"type":21},800,[58],"NA","Carbapenem resistant Enterobacteriaceae (CRE) colonization of patients discharged from hospitals is a source of transmission to the community. In a cluster randomized controlled trial the effect of a bundle of interventions will be assessed on CRE transmission from CRE+ index patient discharged from hospital to HouseHold (HH) members. The districts in two provinces will be randomized to intervention or control. An information, communication, education and hygiene intervention, developed in collaboration with local health authorities, will aim to improve hygiene and decrease antibiotic (AB) use. The effect will be evaluated on CRE transmission between HH members, livestock and environment through consecutive CRE screening using fecal and hospital effluent samples cultured on carbapenem selective media. Knowledge, Attitudes, Practice surveys with smartphones will assess health seeking, AB use and hygiene adherence, hence detecting the effect of interventions. If transmission of CRE +\u002F- Colistin Resistant Enterobacteriaceae (CoRE, common among livestocks) is detected the source will be investigated including livestock and food, targeted information will be given and evaluated. In hospitals the effect of cohort care will be assessed on CRE acquisition, hospital acquired infection, treatment outcome, costeffectiveness and contamination in sewage water. Mechanisms of resistance, relatedness of CRE isolates in different One Health departments, and rate of CRE transmission from humans to animals and vice versa, will be assessed through Whole Genome Sequencing (WGS).",[30,61],"Carbapenem-Resistant Enterobacteriaceae Infection","2025-06-18",{"date":64,"type":36},"2025-06-24",{"date":66,"type":36},"2022-07-01",{"date":68,"type":21},"2026-06-30",{"name":70,"class":43},"Hanoi University of Public Health",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":53,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100579442","clean-trial---chlorination-to-reduce-enteric-and-antibiotic-resistant-infections-in-neonates-100579442","NCT06824350","Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates","Multi-component Chlorination Intervention to Reduce Neonatal Infections in Rural Health Facilities","CLEAN","Facility Inclusion Criteria:\n\n* Public health care facility\n* 25 live births or more per month\n* Infrastructure compatible with inline chlorination device\n\nParticipant Inclusion Criteria:\n\n* Pregnant adults\u002Fmature minors arriving at enrolled facilities to give birth and their neonates\n\nFacility Exclusion Criteria:\n\n* Existing facility-level chlorination\n\nParticipant Exclusion Criteria:\n\n* Miscarriage (\\\u003C28 weeks gestation)\n* Stillbirth (for neonatal analysis only)\n* Unable to give informed consent\u002Fdo not consent\n* Reside \\>2 hours away from facility for enrollment into swab sampling cohort",{"count":80,"type":21},45450,[58],"The CLEAN (ChLorine to reduce Enteric and Antibiotic resistant infections in Neonates) cluster randomized controlled trial in western Kenya will evaluate the impact of a multi-component chlorination intervention in health care facilities on maternal and neonatal health. Intervention facilities will receive a passive chlorination technology for water supply treatment and a reliable supply of sodium hypochlorite disinfectant. Both intervention and treatment facilities will receive infection prevention and control messaging. The goal of the study is to evaluate the impact of the intervention on bacterial contamination of water supply, on staff hands, and on high-touch surfaces in maternity wards, and the following outcomes among facility-born neonates and their mothers: (1) gut carriage of bacterial pathogens associated with sepsis one week post-birth, (2) gut carriage of antibiotic resistant bacteria one week post-birth, and (3) symptoms of possible serious bacterial infection one week following birth.",[84,85,30,86,87],"Sepsis","Neonatal Mortality","Enteric Infections","Serious Bacterial Infection",[89,90,91,92,93,94,95,96,97],"infection prevention and control","antibiotic resistance","bacterial enteric infection","neonatal mortality","sepsis","water disinfection","chlorine","sodium hypochlorite","hospital acquired infections","2025-05-20",{"date":100,"type":36},"2025-05-25",{"date":102,"type":36},"2025-01-21",{"date":104,"type":21},"2027-07",{"name":106,"class":43},"University of California, Berkeley",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":44},"100477854","phase-3-broad-spectrum-antibiotic-prophylaxis-in-tumor-and-infected-orthopedic-surgery-100477854","NCT05502380","Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery","Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Sur-gery - the Prospective-randomized, Microbiologist-blinded, Stratified, Superiority Trials - BAPTIST Trials","BAPTIST","Inclusion Criteria\n\n* Age ≥ 18 years\n* Surgery under current or recent therapeutic antibiotics (antibiotic-free window \\\u003C14 days and past antibiotic prescription \\>4 days)\n* Surgery for open fractures and wounds; including 2nd and 3rd looks\n* Potentially contaminated wound revision in the operating theatre\n* Tumor (oncologic) surgery (if prior radiotherapy and\u002For bone involvement)\n* Spine surgery with ASA-Score \\>= 3 points, sacral involvement, or re-vision surgery\n* Known skin colonization with multidrug-resistant Gram-negative bacteria\n\nExclusion Criteria:\n\n* Inability to understand the study procedure for linguistic or cognitive rea-sons\n* Surgery without intraoperative microbiological samples\n* Allergy or major intolerance to vancomycin and\u002For gentamicin\n* Anticipated clinical follow-up of less than 6 weeks after inclusion\n* Pregnant or breastfeeding women\n* Known carriage of multiresistant Gram-negative bacteria in the urine or anal region",{"count":20,"type":21},[25],"The perioperative antibiotic prophylaxis is evidence-based in orthopedic surgery. While its duration ranges from a single dose to three doses throughout the world, the choice of the prophylactic agents is undisputed. Worldwide, the surgeons use 1st or 2nd-generation cephalosporins (or vancomycin in some cases).\n\nHowever, there are particular clinical situation with a high risk of antibiotic-resistant surgical site infections (SSI); independently of the duration of adminis-tered prophylaxis. These resistant SSI's occur in contaminated wounds, or during surgery under current therapeutic antibiotics, and base on \"selection\" by antibiotics used for therapy or for prophylaxis.",[120,121,30],"Surgical Site Infection","Microbial Colonization",[123,124,125,126],"Perioperative antibiotic prophylaxis","Selection","High Risk patients","Ranndomized-Controlled Trial","2024-11-28",{"date":129,"type":36},"2024-12-02",{"date":131,"type":36},"2022-09-15",{"date":133,"type":21},"2025-12-12",{"name":135,"class":43},"Balgrist University Hospital",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":44},"100562801","phase-4-the-role-of-postoperative-antibiotics-in-laparoscopic-cholecystectomy-100562801","NCT06607887","The Role of Postoperative Antibiotics in Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Adult patients (aged above 18 years) undergoing laparoscopic cholecystectomy.\n\nExclusion Criteria:\n\n* patients with comorbidities (Diabetes, malignancies, Immunosuppressed). Lost of follow-up. Patients received antibiotics within 72 hr before admission. Complicated cases involved, gangrenous and perforated cholecystitis and abscess.",{"count":143,"type":21},300,[145],"PHASE4","Comparison between postoperative parenteral prophylactic antibiotics, and oral antibiotics regarding the incidence of post laparoscopic cholecystectomy infection.",[148,30],"Infection Wound",[150,151,152,153],"antibiotic","prophylaxis","cholecystectomy","postoperative","2024-09-19",{"date":156,"type":36},"2024-09-23",{"date":158,"type":36},"2024-08-30",{"date":160,"type":21},"2024-12-30",{"name":162,"class":43},"Minia University Hospital",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":107},"100535955","dynamics-of-colonization-and-infection-by-multidrug-resistant-pathogens-in-immunocompromised-and-critically-ill-patients-100535955","NCT06258551","Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients","DYNAMITE","Inclusion Criteria:\n\n* Admission to an intensive care unit or stem cell transplant unit (for allogeneic stem cell transplantation) within previous 24 hours\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Pregnancy\n* History of inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* Gastrointestinal derivation (colostomy, ileostomy, etc.)",{"count":171,"type":21},1000,"OBSERVATIONAL","The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or decrease the risk of acquiring an infection or becoming colonized by pathogenic bacteria. Participants will have the following samples collected during enrollment: stool samples (maximum 2x\u002Fweek), blood draws (1x\u002Fweek), oral swab (1x\u002Fweek).",[175,30,176,61,177,178,179,180],"Antimicrobial Drug Resistance","Clostridium Difficile","Extended Spectrum Beta-Lactamase Producing Bacteria Infection","Vancomycin Resistant Enterococci Infection","Carbapenem Resistant Bacterial Infection","Vancomycin-Resistant Enterococcal Infection","2024-02-06",{"date":183,"type":36},"2024-02-14",{"date":185,"type":36},"2020-12-08",{"date":187,"type":21},"2026-06",{"name":189,"class":43},"The Methodist Hospital Research Institute",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":44},"100482397","helicobacter-pylori-local-prevalence-and-antibiotic-resistance-100482397","NCT05561504","Helicobacter Pylori Local Prevalence and Antibiotic Resistance","HelicoPTER - Bestimmung Der Lokalen Helicobacter Pylori Prävalenz Und Antibiotika Resistenzlage","HelicoPTER","Inclusion Criteria:\n\n* Minimum age of 18 years\n* informed consent for HelicoPTER study\n* informed consent for HEPY biobank\n\nExclusion Criteria:\n\n* no capacity to consent",{"count":199,"type":21},20000,"The clinical management of H. pylori infection depends essentially on two factors, prevalence and local resistance. In Germany, only limited data from rather small cohorts currently exist regarding both factors. Knowledge of the current prevalence (accounting for socioeconomic factors and age) is important for the selection of suitable detection methods, as this influences the positive and negative predictive value of the respective diagnostic methods. Current data on antibiotic resistance are essential for efficient therapy. In this clinical study, we will collect data on the frequency and severity of H. pylori infections and then, after endoscopic examination, on antibiotic resistance. Knowledge of the resistance situation is necessary for the selection of suitable therapeutic regimens. Furthermore, molecular methods for resistance detection are to be compared with conventional microbiological methods in order to be able to detect resistance more quickly. Furthermore, we aim to identify specific parameters for early detection of patients at particularly high risk of gastric cancer or with precancerous lesions due to infection. The aim is to identify carcinogenesis-relevant factors such as gastric microbiome signatures that will make it possible to identify patients who are most likely to benefit from prophylactic eradication therapy in terms of risk stratification.",[202,203,204,30,205,121],"Helicobacter Pylori Infection","Helicobacter Pylori Gastritis","Drug Resistant Bacterial Infection","Gastric Cancer","2023-11-29",{"date":208,"type":36},"2023-11-30",{"date":210,"type":36},"2021-03-31",{"date":212,"type":21},"2035-12-31",{"name":214,"class":43},"Technical University of Munich",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":229,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100518259","chinese-hospital-acquired-pneumonia-collaboration-network-epidemiology-diagnosis-and-treatment-100518259","NCT06028217","Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment","A Prospective Study on Pathogen Investigation, Risk Factors, and Prognostic Factors Analysis of Hospital Acquired Pneumonia (HAP)","CHAPTER","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Meets the clinical diagnostic criteria for HAP in the 2018 HAP\u002FVAP guidelines. Chest X-ray or CT shows new or progressive infiltrative shadows, consolidation shadows, or ground glass shadows, combined with 2 or more of the following 3 clinical symptoms, to establish a clinical diagnosis: 1) Fever, body temperature\\>38 ℃; 2) Purulent airway secretions; 3) Peripheral blood white blood cell count \\>10 × 10\\^9\u002FL or \\\u003C4 × 10\\^9\u002FL.\n3. Having qualified evidence of responsible pathogen. On the basis of clinical diagnosis, one of the following conditions should be met simultaneously: 1) Qualified lower respiratory tract secretions (neutrophil count \\>25\u002Flow magnification field, epithelial cell count \\\u003C10\u002Flow magnification field, or a ratio of the two \\>2.5:1), pathogenic bacteria cultured through bronchoscopy anti pollution brush (PSB), bronchoalveolar lavage fluid (BALF), lung tissue or sterile body fluid, and consistent with clinical manifestations; 2) Pathology, cytopathology, or direct microscopic examination of lung tissue specimens showing fungi and evidence of tissue damage; 3) The serum IgM antibodies of atypical pathogens or viruses change from negative to positive, or the titers of specific IgG antibodies in both acute and recovery phases show a 4-fold or more change. During the outbreak of respiratory viruses and with a history of epidemiological contact, respiratory secretions were tested positive for corresponding virus antigens, nucleic acid tests, or virus culture.\n4. obtained informed consent\n\nExclusion Criteria:\n\n1. Those who cannot understand and execute the investigation plan.\n2. Active pulmonary tuberculosis;\n3. Severely immunosuppressed patients: absolute neutrophil count \\\u003C0.5× 10\\^9\u002FL, CD4\\\u003C200\u002Fml.","100 Years",{"count":225,"type":21},4000,"The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China.\n\nThe main purposes of this study are:\n\n1. clarify the regional differences and changes over time in the pathogen spectrum and antibiotic resistance rate among HAP patients in China;\n2. build a continuously optimized nationwide HAP pathogen and antibiotic resistance surveillance network;\n3. identify the molecular epidemiology of common pathogens",[228,30],"Hospital-acquired Pneumonia","NOT_YET_RECRUITING","2023-08-31",{"date":232,"type":36},"2023-09-08",{"date":234,"type":21},"2023-10-01",{"date":236,"type":21},"2027-12-31",{"name":238,"class":43},"Ruijin Hospital",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":264},"100456500","phase-3-pivmecillinam-with-amoxicillinclavulanic-acid-for-step-down-oral-therapy-in-esbl-utis-100456500","NCT05224401","Pivmecillinam With Amoxicillin\u002FClavulanic Acid for Step Down Oral Therapy in ESBL UTIs","Pivmecillinam With Amoxicillin\u002FClavulanic Acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales (PACUTI)","PACUTI","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Fever (≥ 38.3 C) or shaking chills at least once at home or in hospital\n3. Clinical suspicion of UTI including at least one of the following symptoms:\n\n   1. Dysuria, urinary urgency, difficulty urinating, new or worsened urinary incontinence, macroscopic haematuria or increased urinary frequency\n   2. Low abdominal pain or flank pain with percussion or palpation tenderness over kidneys and\u002For bladder.\n4. Urine (≥ 103 CFU\u002FmL) and\u002For blood culture positive for EPE\\* with susceptibility to pivmecillinam†.\n5. In-patient who has received 1-5 days of EPE-active‡ intravenous antibiotics\n6. Discontinuing parenteral treatment and starting treatment with oral antibiotics is considered safe according to the treating physician.\n\n   * EPE refers to ESBL-producing Enterobacterales. This includes Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Klebsiella oxytoca, and Citrobacter koseri.\n\n     * Susceptibility for pivmecillinam in the study is based on zone diameter breakpoints for pyelonephritis (≥ 20 mm) which was received by personal communication with professor Christian Giske, the chairman of the European Committee of Antimicrobial Susceptibility Testing (EUCAST) (26).\n\n       * EPE-active intravenous antibiotics refers to EUCAST susceptibility testing and will most often be piperacillin-tazobactam, meropenem or imipenem-cilastatin in the Swedish setting, and less often aminoglycosides or newer beta-lactamase-inhibitor-containing beta-lactam antibiotics (27). Participants who have only received one dose of EPE-active intravenous antibiotics are also eligible and are considered within the \"1-5 days\" of antibiotics.\n\nPatients may only be recruited and randomised once in this trial.\n\nExclusion criteria (any of the following)\n\n1. Known or suspected pregnancy.\n2. Known or suspected life-threatening allergy towards beta-lactam antibiotics.\n3. Clinical isolate of EPE is resistant to ciprofloxacin, TMX and ertapenem.\n4. Severe renal insufficiency with estimated glomerular filtration rate (eGFR) \\\u003C10mL\u002Fmin or requiring any form of dialysis.\n5. Severe decompensated liver failure (i.e., child Pugh class B or C).\n6. Genetic metabolic diseases associated with severe carnitine deficiency.\n7. Megaloblastic haematopoiesis.\n8. Co-treatment with valproate or valproic acid (due to interaction with pivmecillinam and ertapenem respectively)\n9. Other reason to which patient is unfit to be included in the study according to treating physician, e.g., cognitive impairment preventing informed consent and follow-up, inability to speak and\u002For read Swedish, missing national personal identification number or missing telephone number preventing follow-up or planned duration of antibiotics \\> 10 days due to complicating factors.","130 Years",{"count":249,"type":21},330,[25],"To evaluate if the combination of pivmecillinam and clavulanic acid (PAC) is non-inferior to ciprofloxacin, trimethoprim-sulfamethoxazole or ertapenem as step down oral therapy in patients with febrile UTI caused by extended spectrum beta-lactamase (ESBL) producing Enterobacterales (EPE).",[253,254,30],"Urinary Tract Infections","Bacteremia","2023-08-25",{"date":257,"type":36},"2023-08-28",{"date":259,"type":36},"2023-05-29",{"date":261,"type":21},"2027-09-01",{"name":263,"class":43},"Lund University",5]